Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: A multicentric study

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Dumurgier, Julien ^a,b   Schraen, Susanna ^c,d   Gabelle, Audrey ^e   Vercruysse, Olivier ^d   Bombois, Stéphanie ^d   Laplanche, Jean Louis ^f   Peoc'h, Katell ^f   Sablonnière, Bernard ^c,d   Kastanenka, Ksenia V ^g   Delaby, Constance ^e   Pasquier, Florence ^d   Touchon, Jacques ^e   Hugon, Jacques ^a,b   Paquet, Claire ^a,b   Lehmann, Sylvain ^e  

^a HÔPITAL FERNAND WIDAL   (France)

^b University of Paris   (France)

^c UNIV LILLE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIV MONTPELLIER   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; TAU181 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA 42 40 RATIO; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FRANCE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

EID: 84930205601     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0114-5     Document Type: Article

References (28)

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63-75.e2.
2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-9.
3. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266-73.
4. Mouton-Liger F, Wallon D, Troussière AC, Yatimi R, Dumurgier J, Magnin E, et al. Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. J Neurol. 2014;261:144-51.
5. Rosén C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener. 2013;8:20.
6. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804.
7. Dumurgier J, Vercruysse O, Paquet C, Bombois S, Chaulet C, Laplanche JL, et al. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimers Dement. 2013;9:406-13.
8. Dumurgier J, Laplanche JL, Mouton-Liger F, Lapalus P, Indart S, Prévot M, et al. The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. J Neurol. 2014;261:1187-95.
9. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013;9:251-61.
10. Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H, et al. Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load. J Neurochem. 2007;101:1053-9.
11. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545-55.
12. 181P levels. J Alzheimers Dis. 2013;36:759-67.
13. 1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis. 2012;29:229-38.
14. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, et al. Amyloid β 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol. 2005;58:139-42.
15. Spies PE, Slats D, Sjögren JM, Kremer BP, Verhey FR, Rikkert MG, et al. The cerebrospinal fluid amyloid β42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res. 2010;7:470-6.
16. 42 increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. J Alzheimers Dis. 2014;41:377-86.
17. Troussière AC, Wallon D, Mouton-Liger F, Yatimi R, Robert P, Hugon J, et al. Who needs cerebrospinal biomarkers? A national survey in clinical practice. J Alzheimers Dis. 2014;40:857-61.
18. Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, et al. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. J Alzheimers Dis. 2013;34:297-305.
19. Dumurgier J, Gabelle A, Vercruysse O, Bombois S, Laplanche JL, Peoc'h K, et al. Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiol Dis. 2013;54:486-91.
20. Lehmann S, Dumurgier J, Schraen S, Wallon D, Blanc F, Magnin E, et al. A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimers Res Ther. 2014;6:38.
21. Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, et al. Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. Alzheimers Dement. 2014;10(5 Suppl):S390-S394.e2.
22. Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-72.
23. Pencina MJ, D'Agostino Sr RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
24. Centre Mémoire de Ressources et de Recherche, Paris Nord Ile-de-France. Net Reclassification Improvement (NRI) calculator. Retrieved from http://www.parisnord.org/net-reclassification-improvement-excell-calculator.html. Accessed 24 Mar 2015.
25. 40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis. 2010;20:445-52.
26. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Trenkwalder C, Brechlin P, et al. CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. J Neural Transm. 2006;113:1771-8.
27. 1-40 ratio measured by α-LISA to distinguish Alzheimer's disease from other dementia disorders. Dement Geriatr Cogn Disord. 2013;36:99-110.
28. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, et al. Prediction of Alzheimer's disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23:316-20.